Osimertinib improves progression-free survival in Asian EGFR-mutated lung cancer patients

Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial.